408 related articles for article (PubMed ID: 25365105)
1. The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data.
Eriksson JK; Askling J; Arkema EV
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-147-9. PubMed ID: 25365105
[TBL] [Abstract][Full Text] [Related]
2. Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care.
Pincus T; Braun J; Kavanaugh A; Smolen JS
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-1. PubMed ID: 25365080
[No Abstract] [Full Text] [Related]
3. The Corrona US registry of rheumatic and autoimmune diseases.
Kremer JM
Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S96-S99. PubMed ID: 27762197
[TBL] [Abstract][Full Text] [Related]
4. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries.
Carmona L; de la Vega M; Ranza R; Casado G; Titton DC; Descalzo MÁ; Gómez-Reino J
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-163-7. PubMed ID: 25365109
[TBL] [Abstract][Full Text] [Related]
5. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.
Dixon WG; Carmona L; Finckh A; Hetland ML; Kvien TK; Landewe R; Listing J; Nicola PJ; Tarp U; Zink A; Askling J
Ann Rheum Dis; 2010 Sep; 69(9):1596-602. PubMed ID: 20525843
[TBL] [Abstract][Full Text] [Related]
6. Overview of the American College of Rheumatology's Electronic Health Record-Enabled Registry: The Rheumatology Informatics System for Effectiveness.
Francisco M; Johansson T; Kazi S
Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S102-S104. PubMed ID: 27762205
[TBL] [Abstract][Full Text] [Related]
7. The British Society for Rheumatology biologics register.
Watson K; Symmons D; Griffiths I; Silman A
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv42-3. PubMed ID: 16239385
[TBL] [Abstract][Full Text] [Related]
8. GISEA: an Italian biological agents registry in rheumatology.
Lapadula G; Ferraccioli G; Ferri C; Punzi L; Trotta F;
Reumatismo; 2011 Nov; 63(3):155-64. PubMed ID: 22257916
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis registries in Sweden.
van Vollenhoven RF; Askling J
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S195-200. PubMed ID: 16273807
[TBL] [Abstract][Full Text] [Related]
10. [Chinese expert-based consensus for methotrexate in rheumatic diseases].
Chinese Association of Rheumatology and Immunology Physicians
Zhonghua Nei Ke Za Zhi; 2018 Oct; 57(10):719-722. PubMed ID: 30293331
[TBL] [Abstract][Full Text] [Related]
11. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?
Wadström H; Eriksson JK; Neovius M; Askling J;
Scand J Rheumatol; 2015; 44(1):22-8. PubMed ID: 25379815
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in Pediatric Rheumatology: July 2015-June 2016.
Sharma A; Vignesh P; Jindal AK; Gupta A
Int J Rheum Dis; 2017 Apr; 20(4):504-509. PubMed ID: 28205425
[No Abstract] [Full Text] [Related]
13. Quality of care in the rheumatic diseases: current status and future directions.
Yazdany J; MacLean CH
Curr Opin Rheumatol; 2008 Mar; 20(2):159-66. PubMed ID: 18349745
[TBL] [Abstract][Full Text] [Related]
14. OPAL: a clinician driven point of care observational data management consortium.
Tymms K; Littlejohn G
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-150-2. PubMed ID: 25365106
[TBL] [Abstract][Full Text] [Related]
15. The National Data Bank for Rheumatic Diseases (NDB).
Michaud K
Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S100-S101. PubMed ID: 27762196
[TBL] [Abstract][Full Text] [Related]
16. [Intra-articular injection of cortisone].
Hammer M; Schwarz T; Ganser G
Z Rheumatol; 2015 Nov; 74(9):774-9. PubMed ID: 26511366
[TBL] [Abstract][Full Text] [Related]
17. Adopting patient-centered care in standard practice: PROMs moving toward disease-specific era.
El Miedany Y
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-40-6. PubMed ID: 25365088
[TBL] [Abstract][Full Text] [Related]
18. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank.
Wolfe F; Michaud K
Rheumatology (Oxford); 2011 Jan; 50(1):16-24. PubMed ID: 20566735
[TBL] [Abstract][Full Text] [Related]
19. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.
Nyberg F; Askling J; Berglind N; Franzén S; Ho M; Holmqvist M; Horne L; Lampl K; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Greenberg JD
Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1121-32. PubMed ID: 26303866
[TBL] [Abstract][Full Text] [Related]
20. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
